These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6148163)

  • 1. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease?
    Madec AM; Laurent MC; Lorcy Y; Le Guerrier AM; Rostagnat-Stefanutti A; Orgiazzi J; Allannic H
    Clin Endocrinol (Oxf); 1984 Sep; 21(3):247-55. PubMed ID: 6148163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.
    Teng CS; Yeung RT
    J Clin Endocrinol Metab; 1980 Jan; 50(1):144-7. PubMed ID: 6892512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease.
    Davies TF; Yeo PP; Evered DC; Clark F; Smith BR; Hall R
    Lancet; 1977 Jun; 1(8023):1181-2. PubMed ID: 68278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
    BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid stimulating antibodies (TSAb) in patients with Graves' disease undergoing antithyroid drug treatment: indicators of activity of disease.
    Karlsson FA; Dahlberg PA
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):579-85. PubMed ID: 6895352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid stimulating antibody: an index of thyroid stimulation in Graves' disease?
    Baldet L; Madec AM; Papachristou C; Stefanutti A; Orgiazzi J; Jaffiol C
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):7-12. PubMed ID: 2889309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that thyroid-stimulating antibody is produced in the thyroid gland.
    Kendall-Taylor P; Knox AJ; Steel NR; Atkinson S
    Lancet; 1984 Mar; 1(8378):654-6. PubMed ID: 6142350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy.
    Hidaka Y; Tamaki H; Iwatani Y; Tada H; Mitsuda N; Amino N
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):15-20. PubMed ID: 7914152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.